Update information
June 2018: We reviewed the evidence on response assessment after chemoradiotherapy and added new recommendations and recommendations for research.
Recommendations are marked as [2018] or [2016].
[2018] indicates that the evidence was reviewed and the recommendation added in 2018.
[2016] indicates that the evidence was last reviewed in 2016.
Minor changes since publication
January 2026: We removed links to NICE's technology appraisal guidance on entrectinib for treating NTRK fusion-positive solid tumours from the sections on systemic anticancer therapy for squamous cell carcinoma of the head, and neck and less common aerodigestive tract cancers. This is because this technology appraisal guidance has been withdrawn.
We also added links to relevant technology appraisal guidance in the sections on systemic anticancer therapy for squamous cell carcinoma of the head and neck airways and less common aerodigestive tract cancers. We also simplified the guideline by removing recommendations on general principles of care that are covered in other NICE guidelines.
ISBN: 978‑1‑4731‑1661‑0